Arovella Therapeutics Ltd

E4NA

Company Profile

  • Business description

    Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

  • Contact

    84 Hotham Street
    Corporate One
    PrestonVIC3072
    AUS

    T: +61 398636472

    https://www.arovella.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    44

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,741.4016.50-0.19%
CAC 407,553.45102.67-1.34%
DAX 4023,057.38260.43-1.12%
Dow JONES (US)42,171.6644.14-0.10%
FTSE 1008,791.8051.67-0.58%
HKSE23,237.74472.95-1.99%
NASDAQ19,546.2725.180.13%
Nikkei 22538,488.34396.81-1.02%
NZX 50 Index12,569.0558.27-0.46%
S&P 5005,980.871.85-0.03%
S&P/ASX 2008,523.707.50-0.09%
SSE Composite Index3,362.1126.70-0.79%

Market Movers